Completed

Effects of Combined Sevoflurane and Nitrous Oxide Inhalation

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

30% Nitrous oxide

+ Placebo

+ 0.2% sevoflurane

DrugOther
Who is being recruted

Narcotic-Related Disorders+9

+ Agnosia

+ Mental Disorders

See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: November 1996
See protocol details

Summary

Principal SponsorUniversity of Chicago
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 1996

Actual date on which the first participant was enrolled.

The purpose of this study is to determine the effects of combined sevoflurane and nitrous oxide inhalation on mood, psychomotor performance, and the pain response in humans.

Official TitleEffects of Combined Sevoflurane and Nitrous Oxide Inhalation
NCT00000262
Principal SponsorUniversity of Chicago
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Narcotic-Related DisordersAgnosiaMental DisordersOpioid-Related DisordersNervous System DiseasesNeurologic ManifestationsPerceptual DisordersSigns and SymptomsPathological Conditions, Signs and SymptomsNeurobehavioral ManifestationsSubstance-Related DisordersChemically-Induced Disorders

Criteria

Please contact site for information.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

33.333% chance of being blinded to the placebo group

Treatment Groups

Group I

Placebo

Group II

Active Comparator

Group III

Active Comparator

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

University of Chicago, Anesthesia & Critical Care

Chicago, United StatesOpen University of Chicago, Anesthesia & Critical Care in Google Maps
CompletedOne Study Center